SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.

NEW YORK, April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Sierra Oncology, Inc. ("Sierra" or the "Company") (NASDAQ: SRRA), in connection with the proposed acquisition of the Company by GlaxoSmithKline plc (NYSE: GSK).  Under the terms of the merger agreement, the Company's shareholders will receive $55.00 in cash for each share of Sierra common stock owned.  The transaction is valued at approximately $1.9 billion. 

Read more at prnewswire.com